Clinical Trial Update: Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating FS VH S/D 500 S-apr (Tisseel) as an adjunct to sutured dural repair in cranial surgery for cerebrospinal fluid leak; completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebrospinal Fluid Leak

Drugs mentioned

• FS VH S/D 500 S-apr (Tisseel)

Snippet

Sponsor: Baxter Healthcare Corporation | Conditions: Cerebrospinal Fluid Leak | Phase 3 | Status: COMPLETED | Results posted: 2019-09-10